Remus Pharmaceuticals shareholders and shareholding pattern
NSE: REMUSPharmaceuticals & Biotechnology
Last close ₹880.60down ₹20.60 (2.29%)
Share price at the NSE close on 23 Oct 2026. Previous close ₹901.20.
52-week range of traded prices to 23 Oct 2026
₹580.00Low, 9 Mar 2026₹1,039.00High, 15 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹1,038 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 20 May 2026
- 28.1
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 20 May 2026
- 3.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 20 May 2026
- 12.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 20 May 2026
- 13.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 20 May 2026
- 0.06
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 2,80085.7% delivered
Who owns Remus Pharmaceuticals, filing by filing
Per cent of the company's shares. Every filing on record, from Sep 2023; the latest is the filing for Sep 2026.
Sep 2026 filing
- Promoters70.95%
- Foreign institutions5.10%
- Indian institutions0.43%
- Individuals and others23.52%
Shareholding pattern, per cent
- Promoters
- Foreign institutions
- Indian institutions
- Individuals and others
| Per cent | Sep 2023Filed 21 Oct | Mar 2024Filed 20 Apr | Sep 2024Filed 18 Oct | Mar 2025Filed 18 Apr | Sep 2025Filed 17 Oct | Mar 2026Filed 17 Apr | Sep 2026Filed 21 Oct |
|---|---|---|---|---|---|---|---|
| 69.61% | 70.60% | 70.84% | 70.85% | 70.91% | 70.95% | 70.95% | |
| Indian promoters | 69.61% | 70.60% | 70.84% | 70.85% | 70.91% | 70.95% | 70.95% |
| Public. Every shareholder outside the promoter group, the employee trusts and the shares held against depositary receipts, as the filing totals them. | 30.39% | 29.40% | 29.16% | 29.15% | 29.09% | 29.05% | 29.05% |
| Shares in issue | 14,73,000 | 14,73,000 | 58,92,000what Shares in issue, Sep 2024, includes. Bonus issue on 6 Jun 2024: 3 new shares for every 1 held. Earlier filings count the shares before it. | 58,92,000 | 1,17,84,000what Shares in issue, Sep 2025, includes. Bonus issue on 4 Jul 2025: 1 new share for every 1 held. Earlier filings count the shares before it. | 1,17,84,000 | 1,17,84,000 |
| Shares locked inShares locked in. Shares the filing reports as barred from sale until a set day, such as promoters' shares after a public issue or shares allotted to an investor directly. | 10,85,000 | 10,85,000 | 11,80,000 | 11,80,000 | 23,60,000 | 23,60,000 | – |
| Promoters' shares locked in | 10,07,125 | 10,07,125 | 11,80,000 | 11,80,000 | 23,60,000 | 23,60,000 | – |
A dash is a line the filing did not state.
Remus Pharmaceuticals promoters
Promoters are the founders, families and companies that control the company, as its filings name them. Every member of the promoter group holding shares in the filing for Sep 2026; the largest is Shah Arpit Deepakkumar, 17.66%. The filing names 35 more members with no shares.Promoter buying and selling
| Holder | ||
|---|---|---|
| Shah Arpit DeepakkumarIndividuals and Hindu undivided families | 17.66% | 20,81,200 |
| Roma Vinodbhai ShahIndividuals and Hindu undivided families | 17.21% | 20,27,800 |
| Swapnil Jatinbhai ShahIndividuals and Hindu undivided families | 16.97% | 20,00,000 |
| Anar Swapnil ShahIndividuals and Hindu undivided families | 16.97% | 20,00,000 |
| Hemant Ishwarlal ModiIndividuals and Hindu undivided families | 1.00% | 1,17,600 |
| Renosen Pharmaceuticals Private LimitedIndian companies, trusts and others | 0.92% | 1,08,500 |
| Mansi Aadarsh ShahIndividuals and Hindu undivided families | 0.07% | 8,000 |
| Sonal Hemantbhai ModiIndividuals and Hindu undivided families | 0.07% | 8,000 |
| Vinodkumar Gandalal ShahIndividuals and Hindu undivided families | 0.06% | 6,800 |
| Alkaben Dipakkumar ShahIndividuals and Hindu undivided families | 0.02% | 2,600 |
| Dhruvalben Vishal ShahIndividuals and Hindu undivided families | 0.01% | 700 |
No promoter shares are reported as pledged.
Largest public holders of Remus Pharmaceuticals, filing by filing
Per cent, on the same shares as the split above.
| Holder | Sep 2023Filed 21 Oct | Mar 2024Filed 20 Apr | Sep 2024Filed 18 Oct | Mar 2025Filed 18 Apr | Sep 2025Filed 17 Oct | Mar 2026Filed 17 Apr | Sep 2026Filed 21 Oct |
|---|---|---|---|---|---|---|---|
| India Emerging Giants Fund LimitedForeign portfolio investors, category I | – | – | – | 4.41% | 4.76% | 4.87% | 4.26% |
| Rekha Gunavanth KumarResident individuals, over ₹2 lakh at face value | 1.09% | 1.09% | 1.09% | 1.09% | 1.09% | 1.09% | 1.09% |
| Iegfl - Multi OpportunityForeign portfolio investors, category I | 2.21% | 2.84% | 2.94% | – | – | – | – |
| Chhattisgarh Investments LimitedCompanies | 2.02% | – | – | – | – | – | – |
A filing names every holder above one per cent, in the company's own words: an insurer's holding can carry one of its funds' names. A dash is a filing that did not name the holder, which includes holding under one per cent.